Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19

View ORCID ProfileLaurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, Bastien Rance, Nicolas Paris, Elisa Salamanca, Elisabeth Polard, Anita Burgun, Jean-Marc Treluyer, View ORCID ProfileAntoine Neuraz On behalf of AP-HP / Universities / Inserm COVID-19 research collaboration; AP-HP Covid CDR Initiative and ‘Entrepôt de Données de Santé’ AP-HP consortium
doi: https://doi.org/10.1101/2020.11.23.20237362
Laurent Chouchana
1Centre Régional de Pharmacovigilance, Département de Pharmacologie, Hôpital Cochin, AP- HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Chouchana
  • For correspondence: laurent.chouchana@aphp.fr
Nathanaël Beeker
2Unité de Recherche clinique, Hôpital Cochin, AP-HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Garcelon
3Centre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris. Paris, France
4Institut Imagine, Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bastien Rance
3Centre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris. Paris, France
5Département d’informatique médicale, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Paris
6Département Web Innovation Données (WIND), Direction des systèmes d’information, AP-HP. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisa Salamanca
6Département Web Innovation Données (WIND), Direction des systèmes d’information, AP-HP. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Polard
7Centre Régional de Pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU Rennes. Rennes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Burgun
3Centre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris. Paris, France
5Département d’informatique médicale, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université de Paris. Paris, France
8Département d’informatique médicale, Hôpital Necker-Enfants Malades, AP-HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Treluyer
1Centre Régional de Pharmacovigilance, Département de Pharmacologie, Hôpital Cochin, AP- HP.Centre – Université de Paris. Paris, France
2Unité de Recherche clinique, Hôpital Cochin, AP-HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Neuraz
3Centre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris. Paris, France
8Département d’informatique médicale, Hôpital Necker-Enfants Malades, AP-HP.Centre – Université de Paris. Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Neuraz
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

In this retrospective multicenter cohort study, we aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19. Of 8,078 hospitalized patients for Covid-19, 3,686 (45.6%) had hypertension including 2043 (55.4%) patients exposed to a renin-angiotensin-aldosterone inhibitors (RAASi), 1624 (44.1%) to calcium channel blockers (CCB) and 1154 (37.7%) to beta-blockers. Overall in-hospital 30-day mortality was 23.1%. Compared to non-users, the risk of mortality was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers users (aOR, 0.80 [0.67-0.95]), and not different in RAASi users. These findings support the continuation of antihypertensive agents in patients with Covid-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by State funding from The French National Research Agency (ANR) under "Investissements d'Avenir" programs (Reference: ANR-10-IAHU-01) and ANR PractikPharma grant (ANR-15-CE23-0028).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of the AP-HP Health Data Warehouse approved this study on April 7th, 2020 (CSE-20-18_COVID19)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available on request. The data underlying this article will be shared on reasonable request to the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19
Laurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, Bastien Rance, Nicolas Paris, Elisa Salamanca, Elisabeth Polard, Anita Burgun, Jean-Marc Treluyer, Antoine Neuraz
medRxiv 2020.11.23.20237362; doi: https://doi.org/10.1101/2020.11.23.20237362
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19
Laurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, Bastien Rance, Nicolas Paris, Elisa Salamanca, Elisabeth Polard, Anita Burgun, Jean-Marc Treluyer, Antoine Neuraz
medRxiv 2020.11.23.20237362; doi: https://doi.org/10.1101/2020.11.23.20237362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1434)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10333)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2653)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (571)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1335)
  • Ophthalmology (403)
  • Orthopedics (152)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2421)
  • Public and Global Health (5031)
  • Radiology and Imaging (902)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)